Healius Limited (ASX: HLS) provided a trading update for FY 2024. The company anticipates the following for the fiscal year:
1- Underlying FY 2024 Earnings Before Interest Tax and Depreciation to be AU$345 million to AU$350 million.
2-Underlying FY 2024 Earnings Before Interest and Tax to be AU$60 million to AU$65 million.
The company's trading update for FY 2024 reveals that lower-than-expected average fees have offset the increase in Pathology volumes for the half-year. This is primarily due to a softer GP market and general inflationary pressure. However, pathology volumes for January to May have shown a 3.9% increase from the previous period.
Healius Limited's transformation program for Pathology is making significant progress, instilling confidence in the company's future. It is expected to exceed the targeted net savings of AU$15 million for FY24. Additionally, Lumus Imaging and Agilex Biolabs are performing well and meeting the company's expectations.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
